赛升药业(300485) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥109,535,330.56, a decrease of 17.46% compared to ¥132,698,154.36 in the same period last year[4] - The net loss attributable to shareholders was ¥190,617,604.88, representing a significant decline of 23,235.01% from a profit of ¥823,935.60 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥15,157,836.06, an increase of 383.81% compared to ¥3,132,988.59 in the same period last year[4] - The total profit for Q1 2024 was -¥225,040,253.45, a decrease of 9,329.95% from a profit of ¥2,438,151.69 in the same period last year[7] - The net profit for the period was -$192.35 million, a decrease of 47,421.38% compared to the previous period's profit of $0.41 million, primarily due to a decrease in fair value changes and investment income from associates[9] - The total comprehensive income amounted to -$192.28 million, reflecting a significant decline of 331,112.04% from the previous total of -$58,054.72, mainly attributed to reduced fair value changes and investment income[9] - The net profit attributable to the parent company was -190,617,604.88 CNY, compared to 823,935.60 CNY in the previous period, indicating a significant decline[23] - The total comprehensive income attributable to the parent company was -190,555,908.62 CNY, compared to 359,413.61 CNY in the previous period[23] Cash Flow - The net cash flow from operating activities was ¥42,114,786.47, a substantial increase of 783.06% from ¥4,769,162.32 in the previous year[4] - Cash received from operating activities decreased by 37.72% to $1.36 million compared to $2.19 million in the previous period, mainly due to reduced inter-company transactions[10] - The total operating cash inflow was 114,104,143.09 CNY, compared to 153,241,637.71 CNY in the previous period, reflecting a decrease[26] - The total operating cash outflow was 71,989,356.62 CNY, down from 148,472,475.39 CNY in the previous period[26] - The cash and cash equivalents at the end of the period were $126.24 million, a decrease of 38.48% from $205.20 million in the previous period, primarily due to increased investment in financial assets[11] - The cash and cash equivalents at the end of the period were 126,240,055.05 CNY, down from 205,198,355.58 CNY at the end of the previous period[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,410,249,504.62, down 5.85% from ¥3,622,201,677.70 at the end of the previous year[4] - The company's total assets decreased to CNY 3,410,249,504.62 from CNY 3,622,201,677.70, a decline of 5.8%[20] - Current assets increased to CNY 1,401,590,451.04 from CNY 1,353,066,844.20, an increase of 3.5%[18] - Non-current assets decreased to CNY 2,008,659,053.58 from CNY 2,269,134,833.50, a decline of 11.5%[19] - The total liabilities decreased to CNY 134,942,399.57 from CNY 154,610,347.67, a reduction of 12.7%[20] - The equity attributable to shareholders decreased to CNY 3,245,458,776.88 from CNY 3,436,014,685.50, a decline of 5.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,337, with no preferred shareholders[13] - The largest shareholder, Ma Xie, holds 49.51% of the shares, amounting to 238.46 million shares, indicating significant ownership concentration[13] Expenses - Research and development expenses decreased by 65.80% to ¥9,168,151.11 from ¥26,803,792.38 in the same period last year[7] - Total operating costs amounted to CNY 103,930,716.38, down from CNY 130,399,239.51, reflecting a reduction of 20.2%[21] Investment Income - The company reported a significant drop in investment income, with a loss of ¥82,973,397.25 compared to a gain of ¥674,100.99 in the previous year, a decline of 12,408.75%[7] - The total cash inflow from investment activities was 164,833,714.82 CNY, down from 440,315,257.64 CNY in the previous period[26] - The net cash flow from investment activities was -36,081,201.81 CNY, worsening from -25,465,487.62 CNY in the previous period[26] - The company reported a 252.40% increase in cash received from investment income, amounting to $13.43 million compared to $3.81 million in the previous period, indicating improved financial management[10]